DK0871465T3 - Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS - Google Patents

Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS

Info

Publication number
DK0871465T3
DK0871465T3 DK96922604T DK96922604T DK0871465T3 DK 0871465 T3 DK0871465 T3 DK 0871465T3 DK 96922604 T DK96922604 T DK 96922604T DK 96922604 T DK96922604 T DK 96922604T DK 0871465 T3 DK0871465 T3 DK 0871465T3
Authority
DK
Denmark
Prior art keywords
ritonavir
abt
cytochrome
pharmacokinetics
improve
Prior art date
Application number
DK96922604T
Other languages
Danish (da)
English (en)
Inventor
Daniel W Norbeck
Dale J Kempf
John M Leonard
Richard J Bertz
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26667933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0871465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0871465T3 publication Critical patent/DK0871465T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK96922604T 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS DK0871465T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65495P 1995-06-29 1995-06-29
US384995P 1995-09-15 1995-09-15
PCT/US1996/011015 WO1997001349A1 (fr) 1995-06-29 1996-06-28 Emploi de ritonavir (abt-538) pour ameliorer la pharmacocinetique de medicaments metabolises par le cytochrome p450 dans une methode de traitement du sida

Publications (1)

Publication Number Publication Date
DK0871465T3 true DK0871465T3 (da) 2003-02-03

Family

ID=26667933

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02079003T DK1284140T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til forbedring af farmakokinetikken hos lægemidler, der metaboliseres af cytochrom P450, ved en metode til behandling af AIDS
DK10185624.3T DK2295052T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450
DK02079004T DK1293207T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
DK96922604T DK0871465T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK02079003T DK1284140T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til forbedring af farmakokinetikken hos lægemidler, der metaboliseres af cytochrom P450, ved en metode til behandling af AIDS
DK10185624.3T DK2295052T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450
DK02079004T DK1293207T3 (da) 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS

Country Status (14)

Country Link
US (2) US6037157A (fr)
EP (7) EP2295052B1 (fr)
JP (4) JP4023823B2 (fr)
KR (2) KR20070120619A (fr)
AT (2) ATE225186T1 (fr)
AU (1) AU722812B2 (fr)
CA (1) CA2224738C (fr)
DE (3) DE69637511T2 (fr)
DK (4) DK1284140T3 (fr)
ES (4) ES2304416T3 (fr)
HK (1) HK1049103A1 (fr)
IL (1) IL122546A (fr)
PT (4) PT1293207E (fr)
WO (1) WO1997001349A1 (fr)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DE122007000045I2 (de) 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
NZ335276A (en) * 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
EP0955054A4 (fr) * 1996-11-08 2003-01-29 Japan Energy Corp Medicament contre le sida
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
KR100348561B1 (ko) * 1997-08-12 2002-09-18 주식회사 엘지씨아이 Lb71350과 dmp450을 함유하는 조성물
KR19990016003A (ko) * 1997-08-12 1999-03-05 성재갑 치토크롬 저해제 조성물
KR19990016002A (ko) * 1997-08-12 1999-03-05 성재갑 Ｌｂ71350을 함유하는 치토크롬 ｐ450 기질
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
PT2336134T (pt) † 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
EP1712231A3 (fr) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Methode d'améliorer la cinétique pharmaceutique de tipranavir
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (fr) * 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
ES2676151T3 (es) 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
KR20050085681A (ko) * 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
US7320961B2 (en) * 2003-03-24 2008-01-22 Abbott Laboratories Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2538843A1 (fr) * 2003-09-12 2005-03-24 Vertex Pharmaceuticals Incorporated Modele animal permettant d'etudier l'activite des proteases et les atteintes hepatiques
NZ546663A (en) * 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2389201T3 (es) * 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
JP2007519706A (ja) * 2004-01-30 2007-07-19 ファイザー・インク Ｈｉｖプロテアーゼ阻害剤及びシトクロームｐ４５０酵素活性阻害剤を含んでなる組成物
EP1711515A2 (fr) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20080267915A1 (en) 2004-10-01 2008-10-30 Vertex Pharmaceuticals Hcv Ns3-Ns4a Protease Inhibition
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
EP1814549A2 (fr) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Traitement de l'infection a vih par co-administration de tipranavir et d'uk-427, 857
JP2008521896A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法
WO2006060175A1 (fr) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Procede de traitement d'une infection par le vih par co-administration de tipranavir et de sch-417690
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
EP1919904B1 (fr) * 2005-07-29 2014-01-08 Janssen R&D Ireland Inhibiteurs macrocycliques du virus de l'hépatite c
AR055105A1 (es) * 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014922A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0614637A2 (pt) * 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
ATE496042T1 (de) * 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ES2401661T3 (es) * 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
WO2007062526A1 (fr) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Promedicaments d'inhibiteurs d'aspartyl protease a base de lysine et leurs procedes de fabrication
EP2345652A1 (fr) 2005-12-21 2011-07-20 Abbott Laboratories Composées antivirales
WO2007076035A2 (fr) * 2005-12-21 2007-07-05 Abbott Laboratories Composes antiviraux
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
WO2007081517A2 (fr) 2005-12-21 2007-07-19 Abbott Laboratories Composes anti-viraux
US20070219243A1 (en) * 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1991229A2 (fr) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
CA2645684A1 (fr) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions et procedes d'utilisation de ritonavir pour le traitement du virus de l'hepatite c
JP2009531315A (ja) 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化ｃ型肝炎プロテアーゼインヒビター
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
EP2518079A3 (fr) 2006-04-11 2012-12-12 Novartis AG Inhibiteurs du VHC/VIH et leur utilisation
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
NO347119B1 (no) * 2006-07-07 2023-05-15 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
KR101477822B1 (ko) * 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
US20080161246A1 (en) 2006-08-31 2008-07-03 Abbott Laboratories Cytochrome P450 Oxidase Inhibitors and Uses Thereof
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
WO2008067164A2 (fr) 2006-11-15 2008-06-05 Abbott Laboratories Formulations de dosage pharmaceutique solides
WO2008059046A1 (fr) * 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
RU2481340C2 (ru) * 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Пиримидин-замещенные макроциклические ингибиторы hcv
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
ME02628B (fr) * 2007-02-23 2017-06-20 Gilead Sciences Inc Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
EA200970806A1 (ru) * 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
CN101795674A (zh) * 2007-06-22 2010-08-04 百时美施贵宝公司 含有阿扎那韦的压片组合物
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
DE602008005462D1 (de) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
KR20100040896A (ko) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
EP2436682A1 (fr) * 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
EP2214668A1 (fr) * 2007-10-29 2010-08-11 Cipla Limited Nouvelle combinaison antirétrovirale
US8263549B2 (en) * 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
UA103013C2 (uk) * 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Амідні сполуки як активатори противірусних препаратів
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
JP5750266B2 (ja) * 2008-02-28 2015-07-15 アッヴィ・インコーポレイテッド 錠剤およびその調製
US20090318561A1 (en) * 2008-06-23 2009-12-24 Mutual Pharmaceutical Company, Inc. Colchicine products, method of manufacture, and methods of use
UY31950A (es) * 2008-07-01 2010-01-29 Medivir Ab Inhibidores de ciclopropil-polimerasa
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
JP5564050B2 (ja) * 2008-10-07 2014-07-30 ヤンセン・アールアンドデイ・アイルランド 抗ウイルス薬の効能促進剤としての新規なアミド化合物
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
WO2010070611A1 (fr) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Préparations d'atazanavir
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
CN102264737A (zh) * 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073632B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
WO2010077061A2 (fr) * 2008-12-31 2010-07-08 한올바이오파마 주식회사 Formules pharmaceutiques contenant des médicaments antiviraux
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
EP2396028A2 (fr) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Polythérapie contre le hcv comprenant de l'interféron pégylé, de la ribavirine et de la telaprevir
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20100261731A1 (en) * 2009-04-13 2010-10-14 Abbott Laboratories Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate
WO2010120935A1 (fr) * 2009-04-15 2010-10-21 Abbott Laboratories Composés antiviraux
LT2421527T (lt) * 2009-04-25 2018-09-10 F. Hoffmann-La Roche Ag Farmakokinetinių savybių pagerinimo būdai
EP2853531A3 (fr) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Composés antiviraux
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (fr) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Formes posologiques unitaires d'inhibiteurs de protéase du vih
US20110046227A1 (en) * 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
AU2011210795A1 (en) 2010-01-29 2012-08-02 Vertex Pharmaceuticals Incorporated Therapies for treating Hepatitis C virus infection
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US20140162942A1 (en) * 2010-07-30 2014-06-12 Anima Ghosal Inhibition of cyp3a drug metabolism
CN103179966B (zh) 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
WO2012083164A1 (fr) 2010-12-16 2012-06-21 Abbott Laboratories Composés antiviraux
WO2012083170A1 (fr) 2010-12-16 2012-06-21 Abbott Laboratories Composés antiviraux
WO2012109646A1 (fr) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Traitement du vhc chez des patients infectés par le vih
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2714683A4 (fr) 2011-05-27 2014-11-05 Hetero Research Foundation Ritonavir amorphe co-précipité
WO2013080148A1 (fr) 2011-11-28 2013-06-06 Ranbaxy Laboratories Limited Procédé de préparation d'une dispersion solide de lopinavir et de ritonavir
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP2015526504A (ja) 2012-08-31 2015-09-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
US20160271160A1 (en) 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
WO2015125082A1 (fr) 2014-02-21 2015-08-27 Mylan Laboratories Limited Procédé amélioré pour la préparation de ritonavir
EP3129009A1 (fr) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
EP4178955A1 (fr) 2020-07-11 2023-05-17 Pfizer Inc. Dérivés d'hétéroaryl cétone antiviraux
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11648300B1 (en) * 2022-03-31 2023-05-16 Asavi Llc Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US384995A (en) 1888-06-26 moore
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ES2243959T3 (es) 1990-11-19 2005-12-01 Monsanto Company Inhibidores de proteasas retrovirales.
WO1993023388A1 (fr) 1992-05-20 1993-11-25 G.D. Searle & Co. Procede de production d'intermediaires utiles dans la synthese d'inhibiteurs de proteases retrovirales
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
KR100268694B1 (ko) 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
DK0541168T3 (da) 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ATE116640T1 (de) 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
DE69322127T2 (de) 1992-05-13 1999-06-24 Japan Energy Corp., Tokio/Tokyo Verfahren zur Herstellung von Peptidderivaten und ihrer Salze
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69334250D1 (de) * 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
IL108459A0 (en) 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
EP0618222A3 (en) 1993-03-11 1997-01-02 Ciba Geigy Ag Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
AU676299B2 (en) * 1993-06-28 1997-03-06 Akira Fujishima Photocatalyst composite and process for producing the same
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
WO1995010281A1 (fr) 1993-10-13 1995-04-20 Merck & Co., Inc. Traitement associe pour l'infection par le vih
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
WO1995011992A1 (fr) * 1993-10-27 1995-05-04 The Regents Of The University Of California Composes antiviraux
KR0125117B1 (ko) 1994-06-15 1997-12-05 성재갑 항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
IL114808A (en) * 1994-08-11 1999-10-28 Merck & Co Inc Combinations of protease inhibitors for the treatment of hiv infection and aids
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0987853A1 (fr) 1998-09-17 2000-03-22 STMicroelectronics S.r.l. Appareil pour l'alignement de la phase entièrement numérique
TWI519686B (zh) 2005-12-15 2016-02-01 聖戈班晶體探測器公司 低差排密度氮化鎵（ＧａＮ）之生長方法
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap

Also Published As

Publication number Publication date
JP4023823B2 (ja) 2007-12-19
AU722812B2 (en) 2000-08-10
KR100824547B1 (ko) 2008-11-04
CA2224738C (fr) 2002-08-27
US20020039998A1 (en) 2002-04-04
HK1049103A1 (en) 2003-05-02
EP1284140B1 (fr) 2008-04-23
IL122546A (en) 2012-01-31
EP2130534A1 (fr) 2009-12-09
DK1293207T3 (da) 2009-10-05
JP2015013878A (ja) 2015-01-22
EP2295052A1 (fr) 2011-03-16
ES2304416T3 (es) 2008-10-16
ES2186787T3 (es) 2003-05-16
EP1293207A1 (fr) 2003-03-19
KR20070120619A (ko) 2007-12-24
JP2012111775A (ja) 2012-06-14
ES2328559T3 (es) 2009-11-16
WO1997001349A1 (fr) 1997-01-16
EP0871465A1 (fr) 1998-10-21
JPH11508884A (ja) 1999-08-03
DE69637511D1 (de) 2008-06-05
DE69637976D1 (de) 2009-09-03
HK1016088A1 (en) 1999-10-29
MX9710403A (es) 1998-07-31
ES2441736T3 (es) 2014-02-06
EP1284140A3 (fr) 2003-03-19
PT1284140E (pt) 2008-05-14
PT1293207E (pt) 2009-08-11
PT871465E (pt) 2003-02-28
EP1210941A2 (fr) 2002-06-05
US6703403B2 (en) 2004-03-09
EP1284140A2 (fr) 2003-02-19
HK1053782A1 (en) 2003-11-07
AU6342096A (en) 1997-01-30
DE69637511T2 (de) 2009-06-04
EP1273298A3 (fr) 2003-03-19
EP2295052B1 (fr) 2014-01-08
ATE392895T1 (de) 2008-05-15
JP5364871B2 (ja) 2013-12-11
EP1293207B1 (fr) 2009-07-22
HK1053783A1 (en) 2003-11-07
DK1284140T3 (da) 2008-08-18
EP0871465B1 (fr) 2002-10-02
EP1273298A2 (fr) 2003-01-08
DE69624136D1 (de) 2002-11-07
PT2295052E (pt) 2014-01-23
US6037157A (en) 2000-03-14
DK2295052T3 (da) 2014-01-20
ATE225186T1 (de) 2002-10-15
JP2007291131A (ja) 2007-11-08
IL122546A0 (en) 1998-06-15
KR19990028407A (ko) 1999-04-15
CA2224738A1 (fr) 1997-01-16
EP1210941A3 (fr) 2002-07-31
DE69624136T2 (de) 2003-08-14

Similar Documents

Publication Publication Date Title
DK1293207T3 (da) Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
NL300385I1 (nl) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
MY164523A (en) Methods and compositions for treating hepatitis c virus
MY138860A (en) Hiv protease inhibitors.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
DE69430385D1 (de) Hiv-proteaseinhibitoren
ZA991029B (en) Composition and methods for treatment of hiv infections.
DE60128100D1 (de) Analgetisches arzneimittel
FI973184A7 (fi) Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibi ittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdoll isesti yhdessä AZT:n, DDI:n tai DDC:n kanssa
WO2001014576A3 (fr) Methodes efficaces de preparation d'inhibiteurs de protease de rhinovirus, intermediaires cles et reacteur a membrane continue utile dans leur preparation
SE9602262D0 (sv) New use of derivatives of cystine
EP0774969B8 (fr) Combinaison de l'inhibiteur de la protease du vih
WO2002096359A3 (fr) Inhibiteurs de la protease du vih pentanamide piperazine
EP1549642A4 (fr) Derives de 6-methylpyridine, procede d'elaboration, et composition pharmaceutique antivirale renfermant ces derives
FI970565A0 (fi) HIV-proteaasia inhiboiva yhdistelmä
SE9900438D0 (sv) The pharmacological use of certian cystine derivatives